The Addressing Behavior Change intervention, which can be delivered by dermatologists in less than 3 minutes, is associated with improvements in people’s sun protection behavior that last several months, findings indicate.
Treatment with tumour necrosis factor inhibitors is not associated with a significantly increased risk of recurrent cancer among patients with rheumatoid arthritis, researchers report.
Oral etoposide plus apatinib is associated with a good objective response rate and manageable toxicity in heavily pretreated Chinese women with platinum-resistant or refractory ovarian cancer, according to results of the phase II AEROC study.
Patients who receive antiviral therapy for more than 90 days prior to hepatectomy for hepatitis B virus-related hepatocellular carcinoma have a reduced risk for microvascular invasion and early tumor recurrence, Chinese research shows.
Phase II trial results suggest that the Bruton tyrosine kinase inhibitor ibrutinib has high activity and is well tolerated in symptomatic, treatment-naïve patients with Waldenström macroglobulinemia.